Compare ENHA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENHA | VALN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Singapore | France |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.1M | 653.3M |
| IPO Year | 2025 | 2021 |
| Metric | ENHA | VALN |
|---|---|---|
| Price | $1.57 | $6.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.3M | 81.9K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.48 | $4.75 |
| 52 Week High | $4.60 | $12.23 |
| Indicator | ENHA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 30.19 | 57.83 |
| Support Level | $1.50 | $5.10 |
| Resistance Level | $1.71 | $7.31 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 27.26 | 47.78 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.